Investing.com - Financial Markets Worldwide
Open in App

Shijiazhuang Yiling Pharmaceutical Co Ltd (002603)

Shenzhen
Currency in CNY
15.87
+0.15(+0.95%)
Closed·

002603 Financial Summary

Key Ratios

P/E Ratio19.29
Price/Book2.44
Debt / Equity0.2%
Return on Equity12.62%
Dividend Yield5.09%
EBITDA2.22B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2019
01/01
2019
31/12
2020
31/12
2022
01/01
2023
01/01
2023
31/12
2024
31/12
2025
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa10,116.7912,532.8410,318.316,512.737,830.74
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa6,417.087,976.455,884.223,026.534,956.18
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa1,518.752,853.441,612.84-837.021,605.28
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa1,343.862,362.761,352.38-724.521,286.48
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa12,904.8416,340.6616,979.3313,319.1713,675
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa2,960.444,850.134,446.72,606.692,208.2
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa9,072.1710,930.1511,43810,202.0910,981.9
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa251.913,669.77102.54656.461,132.78
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa528.693,487.74155.46611.011,776.51
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-506.76-1,994.8-899.221,612.03-1,001.97
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-302.15-637-220.59-2,253.18-513.63
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-280.69857.18-964.03-30.03260.09
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.82%
Dividend Yield
5.09%
Industry Median 1.75%
Annualized payout
0.80
Paid annually
5-Years Growth
-6.89%
Growth Streak
Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.86
(+31.41% Upside)

Earnings

Latest Release
Aug 29, 2026
EPS / Forecast
0.21 / --
Revenue / Forecast
1.63B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Yiling Pharma A's earnings for the latest quarter?

The Yiling Pharma A EPS (TTM) is 0.82. Yiling Pharma A reported sales of 1,634.97, net income of 348.45, and EPS of 0.21 for the latest quarter.

What was Yiling Pharma A's net income for the latest quarter?

Yiling Pharma A's net income for the latest quarter was 348.45.

How did Yiling Pharma A's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2,439.78 million CNY in the previous quarter to 1,634.97 million CNY in the latest quarter, and net income moved from 408.85 million CNY to 348.45 million CNY compared to the previous quarter.

What is Yiling Pharma A's net profit margin on a TTM basis?

Yiling Pharma A's trailing twelve months (TTM) net profit margin is 17.48%.

How does Yiling Pharma A's debt to equity ratio compare to industry standards?

Yiling Pharma A's total debt-to-equity ratio is 0.20%.

What is Yiling Pharma A's return on investment on a TTM basis?

Yiling Pharma A's trailing twelve months (TTM) return on investment (ROI) is 12.62%.

How has Yiling Pharma A's total revenue grown this year?

Yiling Pharma A's total revenue was 2,439.78 million CNY in the previous quarter and 1,634.97 million CNY in the latest quarter.

What is Yiling Pharma A's gross margin on a TTM basis?

Yiling Pharma A's trailing twelve months (TTM) gross margin is 65.17%%.

What was Yiling Pharma A's revenue per share for the latest quarter?

Yiling Pharma A's revenue per share for the latest quarter was 6.96.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.